

**STUDIES ON RARE MARINE ACTINOBACTERIA FOR THE
INHIBITION OF BACTERIAL BIOFILMS AND ANTIBIOTIC
RESISTANCE**

NIKKY GOEL



INDIAN INSTITUTE OF TECHNOLOGY DELHI

FEBRUARY 2025

© Indian Institute of Technology Delhi (IIT-D), New Delhi, 2025

**STUDIES ON RARE MARINE ACTINOBACTERIA FOR THE
INHIBITION OF BACTERIAL BIOFILMS AND ANTIBIOTIC
RESISTANCE**

by

NIKKY GOEL

DEPARTMENT OF CHEMISTRY

*Submitted in fulfillment of the requirements of the degree of
Doctoral of Philosophy*

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

FEBRUARY 2025

Dedicated to My Husband

CERTIFICATE

This is to certify that the thesis entitled “**Studies on rare marine actinobacteria for the inhibition of bacterial biofilms and antibiotic resistance**” being submitted by Ms. NIKKY GOEL to the Indian Institute of Technology Delhi for the award of the degree of Doctor of Philosophy in Chemistry is a record of bonafide research work carried out by her.

Ms. Nikky Goel has worked under my guidance and supervision and has fulfilled the requirements for the submission of the thesis which, to my knowledge, has reached the requisite standard.

The results contained in this dissertation have not been submitted in part or full to any other University or Institute for the award of any degree or diploma.



Date: 25.02.2025 Prof. Sunil Kumar Khare

Place: Delhi Department of Chemistry

Indian Institute of Technology

Delhi

(Supervisor)



Dr. Deepti Jain

Associate Professor

Regional Centre for Biotechnology

Faridabad

(Co-Supervisor)

Acknowledgements

In my endeavor to pursue the Doctor of Philosophy, I've experienced a myriad of emotions that have profoundly shaped me into the person I am today. While recognizing there is still a considerable distance to cover on this academic journey, reflecting on the past five years fills me with a deep sense of gratitude and fulfillment. This expression of gratitude serves as a humble acknowledgment to everyone who has accompanied me on this beautiful journey over the last five years.

First and foremost, I express my profound gratitude to **Lord Shiva**, the embodiment of cosmic consciousness and divine energy. His divine blessings have been my guiding light throughout this academic journey. In moments of challenge and triumph, I felt His divine presence, providing strength, wisdom, and inspiration. I humbly acknowledge **Lord Shiva** as the eternal source of guidance and support on the path to knowledge and enlightenment.

I would like to express my profound gratitude to **Prof. S. K. Khare**, my esteemed PhD supervisor. I sincerely appreciate your competent guidance and unwavering efforts to foster excellence in research. Throughout my academic journey, I have consistently looked up to you as a source of constant encouragement and strength during moments of low spirits. Thank you for guiding me forward and preparing me to confront the world's challenges. Your invaluable suggestions, guidance, advice, and constructive criticisms have consistently contributed to my personal and emotional growth.

I wish to thank my co-supervisor, **Dr. Deepti Jain**, for her invaluable support and guidance throughout my doctoral journey. Her expertise, encouragement, and constructive feedback have played a crucial role in shaping the trajectory of my research. I am truly thankful for her dedication, time, and mentorship, which have significantly contributed to the successful completion of my PhD. Working under her supervision has been a rewarding experience, and I am grateful for the knowledge and skills I have gained through our collaboration.

I am thankful to the Head of the Department, **Prof. Siddharth Pandey**, and former HODs of the

Department, **Prof. Ravi Shankar**, **Prof. A. K. Ganguli**, **Prof. A. J. Elias**, and **Prof. N. D. Kurur**, for providing adequate facilities during my study.

I am incredibly thankful to my SRC members, **Prof. Shashank Deep** (SRC Chairperson), **Prof. Tanmay Dutta** (Internal Expert), and **Prof. Prashant Mishra** (External Expert, Department of Biochemical Engineering and Biotechnology, IIT Delhi) for their kind support, guidance and helpful discussions during my PhD work.

I am indebted to my research collaborator, **Prof. Seema Sood** (Professor, Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India). Her guidance has been instrumental in navigating the realm of clinically isolated pathogens, providing profound insights into antimicrobial resistance. I also extend my sincere thanks to **Mr. Rajendra Singh** for his assistance in handling and working with drug-resistant bacteria.

I would like to acknowledge the **Central Research Facility (CRF)** and **Nanoscale Research Facility (NRF)** at IIT Delhi for providing instrumentation facilities. I thank all the staff members of the Instrumentation Lab, M.Sc Lab, M. Tech Lab, B. Tech Lab and Chemistry Office, Department of Chemistry for their cooperation and assistance.

I would like to extend my gratitude to the **Indian Institute of Technology Delhi** for providing me with an Institute Fellowship and aiding financial support for my PhD.

I am thankful to **Rajan Singh** for helping me with the confocal microscopy at the Advanced Technology Platform Centre (Regional Centre for Biotechnology, Faridabad), Electron Microscope Facility (All India Institute of Medical Sciences, New Delhi) and Scanning Electron Microscope facility (IIT Delhi) for helping me carrying out crucial parts of my experiments.

I would like to extend my sincere gratitude to **Ms. Moumita Ghosh (RCB, Faridabad)**. Her unwavering commitment and dedication during the challenging times of my pregnancy were truly commendable. Moumita played a crucial role in the bioinformatics work, confocal experiments, and manuscript writing, showcasing exceptional skills and resilience. Her contributions have significantly enriched the outcomes of our research, and I am grateful for her valuable support and collaboration int

this journey.

The support from the **EMB Lab** (Enzyme and Microbial Biochemistry Laboratory) shaped me and helped me in my formative years in science. I am grateful to my lab seniors, **Dr. Anshu Gupta, Dr. Ruchi Gaur, Dr. Ram Karan, Dr. Arvind Sinha, Dr. Chetna Joshi, Dr. Sumit Kumar, Dr. Rajeshwari Sinha, Dr. R. Hemamalini, Dr. Ayesha Sadaf, Dr. Jasneet Grewal, Dr. Shubhrima Ghosh, Dr. Neerja Yadav, and Dr. Syeda Warisul Fatima, Dr. Shahenvaz Alam**. Although they have left the lab and excelled in life, they are always available to extend help and support and share belongingness with their juniors and lab mates.

I am thankful to my batchmates, **Mr. Nitin Srivastava, Ms. Pooja, and Ms. Ankita Maurya**, and my lovely juniors, **Ms. Huma Fatima, Ms. Sukriti Srivastava, Ms. Deeksha Gopaliya, Ms. Saniya Zaidi, Ms. Simran Kundral, Mr. Bibhuti B. Das, and Ms. Tanisha** for keeping the lab environment cheerful.

I am grateful to my Lab Post-Docs, **Dr. Shivani Chaturvedi, Dr. Rameshwar Tiwari, Dr. Amrik Bhattacharya, Dr. Arti Pal, Dr. Sunaina Singh** and especially **Dr. Razi Ahmad**, for providing valuable insights into the experiments and discussions.

I am most grateful to **Dr. Sumit Kumar**, former lab post-doc, who helped me in my early scientific years and inculcated my scientific temper. His persistent guidance throughout my PhD is greatly appreciated.

I want to thank my extended family (my friends), **Ms. Akanksha Walia, Ms. Aditi Arora, Ms. Prasanjeet kaur, Ms. Vaishali khokhar**, for always being with me. They always cheer for me on my bad phase and celebrate my happiness. Their friendships are invaluable to me.

My deepest gratitude goes to my parents for their unconditional love and support throughout my life. Had it not been for your patience and strong support, things would have been much more difficult. Your utmost faith and belief in me, the endurance of my fluctuating emotions, numerous moments of frustration and being miles apart can never be summarized in a few lines. **Maa and Papa**, you have been my strongest faith, and your silent prayers were nothing but simple magic. I hope this thesis brings

a smile to you and makes you proud, **Maa and Papa**. I sincerely thank my brothers, **Shubham Goyal and Mukul Goel**, for their constant love, care, encouragement and support. I am incredibly grateful to both of you.

I would like to express my heartfelt appreciation to my husband, **Mr. Tanmay Garg**, for his unwavering support and encouragement throughout the journey. His patience, understanding, and constant motivation have been the pillars of strength that sustained me during challenging times. His belief in my capabilities and the sacrifices made for this endeavor is truly invaluable. This accomplishment is as much his as it is mine, and I am profoundly grateful for his presence in every chapter of this academic pursuit.

In the midst of juggling the complexities and demands of my academic journey, my precious daughter, **Dhyuti Garg**, arrived as an unexpected blessing. Her arrival added a new, beautiful chapter to my life. While navigating through the intricacies of my work, her mere presence and radiant smiles became a source of immeasurable strength and joy. Balancing motherhood and research was challenging, but her unwavering support and the remarkable resilience she displayed during those initial months without her mother by her side made the journey all the more meaningful. While travelling to and fro, looking at her beautiful pictures infused each moment with a sense of purpose and reminded me that, beyond the realm of academia, there is a world filled with love, warmth, and boundless inspiration.

I extend my heartfelt gratitude to my cherished parents-in-law, **Mrs. Mamta Garg (Mumma)** and **Mr. Sanjay Garg (Papa)**, for their unwavering support and understanding throughout my doctoral journey. Your encouragement and belief in my abilities have been a source of strength, and your continuous support has made this academic pursuit possible. Thank you for being a pillar of love and encouragement, enriching my academic endeavours and life in countless ways.

I sincerely appreciate my dear sister-in-law, **Mrs. Kshipra Agarwal** and brother-in-law, **Mr. Sandeep Agarwal**, for their constant encouragement and unwavering support that has added warmth and positivity to my academic journey. In the midst of rigorous academic pursuits, the innocent laughter and boundless joy brought by my nephew, **Divit Agarwal (Bumpy)**, served as a delightful respite. His

presence illuminated my journey, reminding me of the simple joys and wonders of life.

At last, I would like to thank all my family members, friends, and colleagues for their good wishes, encouragement, and support during my PhD.

NIKKY GOEL

Abstract

Antimicrobial resistance (AMR), remains a significant worldwide public health issue, leading to 4.95 million deaths in 2019. If no action is taken, up to 10 million lives could be lost annually due to infections caused by drug-resistant microorganisms by the year 2050, resulting in an economic impact of approximately \$100 trillion on the global economy. Biofilms, consisting of microbial cells embedded in self-produced exopolysaccharides, confer bacterial tolerance and resistance to antibiotics by obstructing penetration. As per the US National Institutes of Health, nearly eighty percent of microbial conditions in the body are associated with biofilms, a significant fraction of which exhibit resistance to conventional antimicrobial therapies. Actinobacterial species are recognised for their ability to produce secondary metabolites comprising antibiotic, antiviral, and anticancer compounds. With more than 7000 compounds produced by *Streptomyces* sp., most of them account for the secondary metabolites of potent antibiotics, making *Streptomyces* the most exploited primary antibiotic-producing source.

The thesis aims to extensively investigate the isolation of rare marine actinobacteria for combating biofilm formation and drug resistance. Specifically, two strains of actinobacteria, namely, *Nocardiopsis lucentensis* EMB25 and *Streptomyces* sp. EMB24 were characterized and investigated for anti-biofilm and antibacterial potential. The highlight of the work is the isolation of rare actinobacteria inhibiting and eradicating the biofilm in *Pseudomonas aeruginosa*, reported for the first time.

The overall objectives of the thesis are as follows:

- Isolation of rare marine actinobacteria to study the effect of secondary metabolites on *P. aeruginosa* PseA biofilms
- Mechanism of secondary metabolites in inhibiting biofilm formation of *P. aeruginosa*

PseA

- Screening and isolation of actinobacteria for the antibacterial effect against drug-resistant bacteria
- Green synthesis of silver nanoparticles to study the antibacterial effect against drug-resistant bacteria.

The present study describes the whole genome analysis and biofilm-inhibiting and biofilm-eradicating potential of actinobacterial isolate identified as *N. lucentensis* EMB25. *N. lucentensis* EMB25 has a 6.5 Mbp genome with 71.62 % GC content. The genome analysis by Basic Local Alignment Search Tool (BLAST) Ring Image Generator (BRIG) revealed it to be closely related to *Nocardiopsis dassonvillei* NOCA502F. Moreover, the work intended to explore the antibiofilm potential of EMB25. Fermentation and extraction of the secondary metabolites was done employing the organic solvent extraction method. The organic extract at 1.56 $\mu\text{g}/\mu\text{L}$ inhibited 50 % biofilm (BIC_{50}), and > 85 % biofilm inhibition was observed at 25 $\mu\text{g}/\mu\text{L}$. The gas chromatography-mass spectrometry (GC-MS/MS) technique identified the total compounds present. After identification, the ligands present in the extract were docked on the LasR and RhlR. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis of the selected metabolites shows that these can be pursued as potential drug candidates. Finally, the mechanism was elucidated through expression analysis of genes regulated by LasR and RhlR in the presence and absence of organic extract. To the best of our knowledge, this is the first time the genus *Nocardiopsis* has been explored to inhibit and eradicate the biofilm of *P. aeruginosa*.

The current unprecedented rate of *Streptomyces* genome mining has led to the creation and usage of bioinformatics tools aimed explicitly at discovering Biosynthetic gene clusters (BGCs). Bacterial antiSMASH is a robust genome-mining tool that enables users to identify, annotate, and evaluate secondary metabolite BGCs easily. Based on the relevance of the

Streptomyces genus as a hub of novel antibiotics, we have isolated *Streptomyces* sp. strain EMB24 from Pen, Maharashtra, India. The *Streptomyces* sp. strain EMB24, with a GC content of 72.40 %, has a genome of 7,252,958 bp. The *Streptomyces* sp. strain EMB24 exhibited potent antibacterial activity against various drug-resistant bacteria growth, namely MRSA, tetracycline-resistant *N. gonorrhoeae*, and *N. gonorrhoea* WHO F evaluated using the agar-plug assay.

Subsequently, green synthesis of silver nanoparticles by *Streptomyces* extract resulted in a 10-30 nm size range confirmed by Field Emission Scanning Electron Microscopy (FESEM) and Transmission Electron Microscopy (TEM) images. The AgNPs exhibit significant antibacterial activity against drug-resistant bacteria, namely *P. aeruginosa*, tetracycline-resistant *N. gonorrhoeae*, *N. gonorrhoea* WHO (F) and MRSA at 5 µg/mL concentration. In addition, we have observed more than 80 % of biofilm inhibition in *P. aeruginosa* at 50 µg/mL concentration of AgNPs. This thesis makes a significant contribution by isolating and characterizing rare marine actinobacteria with promising potential for combating AMR and biofilm-related infections. The discovery of *N. lucentensis* EMB25 and *Streptomyces* sp. EMB24, along with their bioactive compounds, offers novel therapeutic strategies for addressing drug-resistant pathogens and biofilm-associated infections. The antimicrobial activity of green-synthesized AgNPs further highlights the potential of this research in developing alternative antimicrobial treatments.

सार

एंटीमाइक्रोबियल रेजिस्टेंस (एएमआर) एक गंभीर वैश्विक सार्वजनिक स्वास्थ्य समस्या बनी हुई है, जिसके कारण 2019 में लगभग 4.95 मिलियन मौतें हुईं। यदि इस पर ध्यान नहीं दिया गया तो 2050 तक ड्रग-रेजिस्टेंट सूक्ष्मजीवों के कारण होने वाले संक्रमणों से प्रति वर्ष लगभग 10 मिलियन लोगों की मौत हो सकती है, जिससे वैश्विक अर्थव्यवस्था पर लगभग \$100 ट्रिलियन का आर्थिक प्रभाव पड़ सकता है। बायोफिल्म्स, जो कि स्वयं द्वारा निर्मित एक्सोपॉलीसैकेराइड्स में संलग्न माइक्रोबियल कोशिकाओं से बने होते हैं, एंटीबायोटिक्स के प्रवेश को रोककर बैक्टीरिया की सहिष्णुता और प्रतिरोध को बढ़ाते हैं। यूएस नेशनल इंस्टीट्यूट्स ऑफ हेल्थ के अनुसार, शरीर में लगभग अस्सी प्रतिशत माइक्रोबियल स्थितियाँ बायोफिल्म्स से जुड़ी होती हैं, जिनमें से अधिकांश परंपरागत एंटीमाइक्रोबियल उपचारों के प्रति प्रतिरोध प्रदर्शित करती हैं। एक्टिनोबैक्टीरियल प्रजातियों को उनके माध्यमिक मेटाबोलाइट्स, जिनमें एंटीबायोटिक, एंटीवायरल, और एंटी-कैंसर यौगिक शामिल हैं, का उत्पादन करने की क्षमता के लिए पहचाना जाता है। स्ट्रीप्टोमाइसीज प्रजातियों द्वारा उत्पादित 7000 से अधिक यौगिकों में से अधिकांश शक्तिशाली एंटीबायोटिक्स के माध्यमिक मेटाबोलाइट्स हैं, जिससे स्ट्रीप्टोमाइसीज एंटीबायोटिक उत्पादन का प्रमुख स्रोत बन गया है। इस शोध का उद्देश्य दुर्लभ समुद्री एक्टिनोबैक्टीरिया के पृथक्करण पर व्यापक अध्ययन करना है ताकि बायोफिल्म गठन और दवा प्रतिरोध का मुकाबला किया जा सके। विशेष रूप से, एक्टिनोबैक्टीरिया की दो प्रजातियों, नोकार्डियोप्सिस लुसेंटेंसिस EMB25 और स्ट्रीप्टोमाइसीज EMB24, का लक्षण निर्धारण और एंटी-बायोफिल्म तथा जीवाणुरोधी क्षमता के लिए परीक्षण किया गया। इस कार्य की विशेषता यह है कि इसमें पहली बार दुर्लभ एक्टिनोबैक्टीरिया को पृथक् करके *Pseudomonas aeruginosa* में बायोफिल्म को रोकने और नष्ट करने की क्षमता का प्रदर्शन किया गया है।

इस शोध के समग्र उद्देश्य निम्नलिखित हैं:

- दुर्लभ समुद्री एक्टिनोबैक्टीरिया का पृथक्करण कर उनके माध्यमिक मेटाबोलाइट्स का *P. aeruginosa* PseA बायोफिल्म्स पर प्रभाव का अध्ययन।
- *P. aeruginosa* PseA के बायोफिल्म गठन को रोकने में माध्यमिक मेटाबोलाइट्स का तंत्र।
- दवा-प्रतिरोधी बैक्टीरिया के खिलाफ जीवाणुरोधी प्रभाव के लिए एक्टिनोबैक्टीरिया का स्क्रीनिंग और पृथक्करण।
- दवा-प्रतिरोधी बैक्टीरिया के खिलाफ जीवाणुरोधी प्रभाव का अध्ययन करने के लिए चांदी के नैनोकणों का हरित संश्लेषण।

वर्तमान अध्ययन में एक्टिनोबैक्टीरियल पृथक नोकार्डियोप्सिस लुसेंटेंसिस EMB25 का पूरे जीनोम विश्लेषण और बायोफिल्म-रोकने और नष्ट करने की क्षमता का वर्णन किया गया है। EMB25 में 6.5 Mbp का जीनोम और 71.62% GC सामग्री है। बेसिक लोकल अलाइनमेंट सर्च टूल (BLAST) रिंग इमेज जनरेटर (BRIG) द्वारा जीनोम विश्लेषण ने इसे *Nocardiosis dassonvillei* NOCA502F से करीबी रूप से संबंधित पाया। इसके अतिरिक्त, EMB25 की एंटी-बायोफिल्म क्षमता की खोज का लक्ष्य रखा गया। माध्यमिक मेटाबोलाइट्स का किण्वन और निष्कर्षण जैविक सॉल्वेंट निष्कर्षण विधि का उपयोग करके किया गया। 1.56 µg/µL पर जैविक निष्कर्ष ने 50% बायोफिल्म (BIC50) को रोका और 25 µg/µL पर > 85% बायोफिल्म अवरोध देखा गया। गैस क्रोमैटोग्राफी-मास स्पेक्ट्रोमेट्री (GC-MS/MS) तकनीक ने सभी यौगिकों की पहचान की। पहचान के बाद, निष्कर्ष में मौजूद लिगैंड्स को LasR और RhlR पर डॉक किया गया। चुने गए मेटाबोलाइट्स का अवशोषण, वितरण, चयापचय, उत्सर्जन और विषाक्तता (ADMET) विश्लेषण से पता चला कि इन्हें संभावित दवा उम्मीदवारों के रूप में आगे बढ़ाया जा सकता है। अंततः, तंत्र को LasR और RhlR द्वारा नियंत्रित जीनों के अभिव्यक्ति विश्लेषण के माध्यम से स्पष्ट किया गया। हमारी जानकारी के अनुसार, यह पहली बार है जब नोकार्डियोप्सिस प्रजाति का उपयोग *P. aeruginosa* के बायोफिल्म को रोकने और नष्ट करने के लिए किया गया है।

वर्तमान में स्ट्रीप्टोमाइसीज जीनोम खनन की अभूतपूर्व दर ने जैवसिंथेटिक जीन क्लस्टर (BGCs) की खोज के लिए विशेष रूप से बायोइन्फॉर्मेटिक्स टूल्स का निर्माण और उपयोग संभव बना दिया है। बैक्टीरियल antiSMASH एक मजबूत जीनोम-खनन टूल है जो उपयोगकर्ताओं को माध्यमिक मेटाबोलाइट्स BGCs की पहचान, एनोटेशन और मूल्यांकन की सुविधा प्रदान करता है। स्ट्रीप्टोमाइसीज प्रजाति को नए एंटीबायोटिक्स के एक केंद्र के रूप में इसके महत्व को देखते हुए, हमने महाराष्ट्र, भारत के पेन से स्ट्रीप्टोमाइसीज प्रजाति EMB24 को पृथक किया है। EMB24 का जीनोम 7,252,958 bp का है और इसमें 72.40% GC सामग्री है। EMB24 ने विभिन्न दवा-प्रतिरोधी बैक्टीरिया, जैसे कि MRSA, टेट्रासाइक्लिन-प्रतिरोधी *N. gonorrhoeae*, और *N. gonorrhoeae* WHO F के खिलाफ एंटीबैक्टीरियल गतिविधि का प्रदर्शन किया है, जिसे एगर-प्लग विधि से आंका गया है।

इसके बाद, स्ट्रीप्टोमाइसीज निष्कर्ष द्वारा हरित संश्लेषित चांदी के नैनोकणों का आकार 10-30 nm पाया गया, जिसकी पुष्टि फील्ड एमिशन स्कैनिंग इलेक्ट्रॉन माइक्रोस्कोपी (FESEM) और ट्रांसमिशन इलेक्ट्रॉन माइक्रोस्कोपी (TEM) इमेजेस द्वारा की गई। 5 µg/mL पर इन AgNPs ने *P. aeruginosa*, टेट्रासाइक्लिन-प्रतिरोधी *N. gonorrhoeae*, *N. gonorrhoeae* WHO (F) और MRSA के खिलाफ महत्वपूर्ण जीवाणुरोधी गतिविधि का प्रदर्शन किया। इसके अतिरिक्त, 50 µg/mL AgNPs की सांद्रता पर *P. aeruginosa* में 80% से अधिक बायोफिल्म अवरोध देखा गया। यह शोध दुर्लभ समुद्री एक्टिनोबैक्टीरिया को पृथक कर, उनके जैव सक्रिय यौगिकों की खोज कर, एएमआर और बायोफिल्म-संबंधित संक्रमणों का मुकाबला करने के लिए एक महत्वपूर्ण योगदान देता है। EMB25 और *Streptomyces* EMB24 का पता लगाना और उनके जैव सक्रिय यौगिकों की पहचान नई चिकित्सीय रणनीतियों को प्रस्तुत करती है जो दवा-प्रतिरोधी रोगजनकों और बायोफिल्म-संबंधित संक्रमणों का समाधान प्रदान करती हैं। हरित संश्लेषित AgNPs की एंटीमाइक्रोबियल गतिविधि इस शोध की महत्वपूर्ण क्षमता को वैकल्पिक एंटीमाइक्रोबियल उपचार विकसित करने में रेखांकित करती है।

Table of Contents

Certificate	i
Acknowledgement	ii
Abstract	vii
Table of contents	xiii
List of Figures	xx
List of Tables	xxix
CHAPTER 1 INTRODUCTION	1-45
1.1 Rationale of the thesis	1
1.2 Objectives	4
1.3 Scope of the thesis	5
1.4 Review of literature	7
1.4.1 Antibiotics: Evolution, Impact, and Prospects	7
1.4.2 Antimicrobial resistance: A Global concern	15
1.4.3 Mechanisms underlying antimicrobial resistance	17
1.4.4 Biofilms	22
1.4.5 Mechanistic insights of biofilm formation	23
1.4.6 Effect of biofilms on human health	29
1.4.7 Biofilm- imparting resistance towards antibiotics	30
1.4.8 Current strategies to inhibit and eradicate the preformed biofilm	33
1.4.9 Actinobacteria: A source of biofilm inhibitors	37
1.4.10 <i>Streptomyces</i> sp.: A hub for a varied array of bioactive	40

molecules

1.4.11 Tapping the potential of marine actinobacteria for novel biofilm 43

inhibitors

CHAPTER 2 ISOLATION AND GENOMIC STUDIES OF 46-81
***NOCARDIOPSIS LUCENTENSIS* EMB25 AND ITS EFFECT ON**
***PSEUDOMONAS AERUGINOSA* PSEA BIOFILMS**

2.1 Introduction 46

2.2 Materials and Methods 47

2.2.1 Target Bacterial Strains and Culture Conditions 47

2.2.2 Sample collection from saline Pen, Maharashtra, India 47

2.2.3 Pre-treatment of soil specimens and selective isolation of 48
actinobacteria

2.2.4 Identification of isolates by 16S rRNA sequencing 48

2.2.5 Screening of biofilm-forming bacteria 49

2.2.6 Screening of actinobacteria isolated for eradication of preformed 49
biofilm

2.2.7 Effect of cell-free extract of potential actinobacteria on preformed 50
biofilm of clinical pathogens

2.2.8 Extraction of genomic DNA of *Nocardiopsis lucentensis* EMB25 50

2.2.9 Carbon source utilization by *Nocardiopsis lucentensis* EMB25 51

2.2.10 Scanning electron microscopy of *Nocardiopsis lucentensis* 51
EMB25

2.2.11 Whole genome sequencing of *Nocardiopsis lucentensis* EMB25 51

2.2.12 Data analysis and genome comparison of *Nocardiopsis* 52
lucentensis EMB25

2.2.13 RAST annotation and Secondary metabolites prediction of <i>Nocardiopsis lucentensis</i> EMB25	53
2.2.14 Antibacterial activity of <i>Nocardiopsis lucentensis</i> EMB25	53
2.2.15 Biofilm eradication activity of <i>Nocardiopsis lucentensis</i> EMB25 cell-free extract and confocal microscopy	54
2.2.16 Statistical analysis	54
2.3 Results and Discussion	55
2.3.1 Sample collection, identification, and phylogenetic analysis	55
2.3.2 Effect of cell-free extract of isolated actinobacteria on biofilms	59
2.3.3 Biofilm eradication potential of cell-free extract on clinical pathogens	62
2.3.4 Biochemical characterization and morphology study of <i>Nocardiopsis lucentensis</i> EMB25	63
2.3.5 Sequencing, assembly, and genomic comparisons of <i>Nocardiopsis lucentensis</i> EMB25	65
2.3.6 Genomic prediction and genome annotation of <i>Nocardiopsis lucentensis</i> EMB25	69
2.3.7 RAST annotation and Secondary metabolites prediction	71
2.3.8 Bioactivity of cell-free extract of <i>Nocardiopsis lucentensis</i> EMB25	77
2.3.9 Data availability	80
2.4 Conclusions	80
CHAPTER 3 THE MECHANISM OF BIOFILM INHIBITION IN <i>P. AERUGINOSA</i> PSEA USING SECONDARY METABOLITES DERIVED FROM <i>NOCARDIOPSIS LUCENTENSIS</i> EMB25	82-111
3.1 Introduction	82

3.2 Materials and Methods	83
3.2.1 Secondary metabolites extraction using organic solvent method	83
3.2.2 Effect of organic extract on preformed biofilm and cell viability	84
3.2.3 Confocal Laser Scanning Microscopic Analysis (CLSM) to study biofilm eradication effect of <i>Nocardiopsis lucentensis</i> EMB25	84
3.2.4 Anti-biofilm activity of <i>Nocardiopsis lucentensis</i> EMB25 and its effect on the growth of planktonic cells	85
3.2.5 Estimation of virulence factor production by <i>Pseudomonas</i> <i>aeruginosa</i> PseA	85
3.2.6 Field Emission Scanning Electron Microscopy (FESEM) to study biofilm inhibition of <i>Pseudomonas aeruginosa</i> PseA	86
3.2.7 Gas Chromatography-Mass Spectrometry analysis to identify metabolites present	87
3.2.8 Computational Studies	87
3.2.9 Extraction of RNA and quantitative gene analysis of quorum sensing genes in <i>Pseudomonas aeruginosa</i> PseA	89
3.2.10 Statistical analysis	90
3.3 Results and Discussion	91
3.3.1 Eradication of preformed <i>Pseudomonas aeruginosa</i> PseA biofilms by ethyl acetate extract	91
3.3.2 Disruption of the architecture of preformed biofilm by ethyl acetate extract	92
3.3.3 Prevention of biofilm formation and effect of ethyl acetate extracts on quorum sensing mediated virulence factors	95
3.3.4 <i>Pseudomonas aeruginosa</i> PseA biofilm growth inhibition study by	99

FESEM	
3.3.5 Compound identification and molecular docking with quorum sensing (QS) regulators	100
3.3.6 Effect of ethyl acetate extract on quorum sensing associated genes	109
3.4 Conclusions	110
CHAPTER 4 GENOMIC STUDIES OF <i>STREPTOMYCES</i> SP. EMB24 AND ITS EFFECT ON MULTIDRUG-RESISTANT BACTERIA	112-135
4.1 Introduction	112
4.2 Materials and Methods	113
4.2.1 Bacterial strains and growth conditions	113
4.2.2 Screening of isolated <i>Streptomyces</i> sp. for antimicrobial activity	114
4.2.3 DNA extraction and 16S rRNA sequencing analysis	115
4.2.4 Illumina and Nanopore Sequencing and assembly of <i>Streptomyces</i> sp. EMB24	116
4.2.5 Genomic prediction and genome annotation of <i>Streptomyces</i> sp. EMB24	117
4.2.6 Phylogeny analysis and Genome comparison of <i>Streptomyces</i> sp. EMB24	117
4.2.7 RAST annotation and Secondary metabolites prediction of <i>Streptomyces</i> sp. EMB24	118
4.3 Results and Discussion	120
4.3.1 Antimicrobial activity against clinical, ATCC and drug-resistant pathogenic bacteria	120
4.3.2 Sequencing, assembly, phylogenetic analysis, and the genomic characteristics	123

4.3.3 Genomic prediction and genome annotation of <i>Streptomyces</i> sp. EMB24	125
4.3.4 RAST annotation and Secondary metabolites prediction of <i>Streptomyces</i> sp. EMB24	128
4.3.4 Data availability	135
4.4 Conclusions	135
CHAPTER 5 BIOLOGICAL SYNTHESIS OF SILVER NANOPARTICLES USING EXTRACT OF <i>STREPTOMYCES</i> SP. EMB24 AND THEIR EFFECT ON DRUG-RESISTANT BACTERIA	136-165
5.1 Introduction	136
5.2 Materials and Methods	137
5.2.1 Materials	137
5.2.2 Biosynthesis of silver nanoparticles	138
5.2.3 UV-Visible spectroscopy of synthesized silver nanoparticles	138
5.2.4 Dynamic light scattering of synthesized silver nanoparticles	139
5.2.5 X-ray diffraction (XRD) of synthesized silver nanoparticles	139
5.2.6 Fourier-transform infrared spectroscopy (FTIR) of synthesized silver nanoparticles	139
5.2.7 Field Emission Scanning Electron Microscopy (FESEM)/ Energy Dispersive X-ray analysis (EDX) of synthesized silver nanoparticles	139
5.2.8 Antimicrobial activity against drug-resistant bacteria	140
5.2.9 Minimum Inhibitory concentration (MIC) and time-kill kinetics of <i>Pseudomonas aeruginosa</i> PseA and Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)	140
5.2.10 Mechanism of action of synthesized silver nanoparticles	141

5.2.11 Inhibition of <i>Pseudomonas aeruginosa</i> PseA Biofilm by synthesize silver nanoparticles	143
5.2.12 Eradication of preformed <i>Pseudomonas aeruginosa</i> PseA Biofilm by synthesize silver nanoparticles	144
5.3 Results and Discussion	145
5.3.1 Characterization of biologically synthesized AgNPs	146
5.3.2 Antibacterial activity of synthesized silver nanoparticles against drug-resistant bacteria	152
5.3.3 Mechanism of action of synthesized silver nanoparticles acting on drug-resistant bacteria	156
5.3.4 Antibiofilm activity of synthesized silver nanoparticles against <i>Pseudomonas aeruginosa</i> PseA	162
5.4 Conclusions	165
CHAPTER 6 OVERALL CONCLUSIONS	167
COLLABORATIVE WORK	169
FUTURE PERSPECTIVES	170
REFERENCES	171
LIST OF PUBLICATIONS	204
BRIEF-BIODATA	206

List of Figures

Figure 1.1	The causes and number of deaths in 2019 (left) and the projections of death due to AMR in 2050 (right) (data adapted from Murray et al., 2022)	1
Figure 1.2	Timelines in which new types of antibiotics were made available for use in medicine (adopted from Hutchings et al., 2019)	10
Figure 1.3	Traditional and non-traditional antibacterials in clinical trials (Phase I, II, and III) as per WHO 2021 (data adapted from https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens)	12
Figure 1.4	Various mechanisms of antibacterial action of silver nanoparticles	15
Figure 1.5	The targets of various antibiotics and associated mechanisms of resistance	18
Figure 1.6	The four stages of biofilm formation: (I) Reversible attachment of free-living bacteria to the compatible surface via the use of cell appendages followed by the irreversible attachment via secreted adhesins. (II) discrete colonies formation known as microcolonies having around 100 bacteria per cluster via upregulation of genes required to maintain attachment. (III) Biofilm maturation via upregulation of EPS genes, the release of polysaccharides, eDNA, and QS molecules. (IV) After a certain period of time, nutrients are depleted, and toxic compounds start to accumulate; this is when the dispersal of bacteria residing in biofilm occurs (adopted from Goel et al., 2021)	27
Figure 1.7	Biofilms-associated infections on surfaces like catheters, teeth, and kidney stones, as well as infections that occur on tissues like the lungs of	29

	CF patients, chronic wounds, and tonsils	
Figure 1.8	Antibiotic (drug) tolerance that biofilms exhibit at the community level	32
Figure 1.9	Ecological distribution of Actinobacteria (adopted from Goel et al., 2021)	37
Figure 2.1	Sample collection sites (salt pans, Mangrove, Creek) for the isolation of rare actinobacteria, Pen, Maharashtra, India	55
Figure 2.2	(A) The calcareous-like colonies were selected and streaked on AIA media, (B) purified for genomic DNA isolation, (C) the isolated genomic DNA was run on 1 % agarose gel and identified using 16S rRNA sequencing results	56
Figure 2.3	The biofilm formation by various gram-positive and gram-negative bacteria ($p < 0.01$)	58
Figure 2.4	Effect of cell-free extract of <i>Streptomyces</i> sp. EMB24, <i>Streptomyces</i> sp. EMB27, <i>Streptomyces</i> sp. EMB28, and <i>Streptomyces</i> sp. EMB29 isolated in the lab, used at concentrations 0.75 %, 0.5 %, 0.25 %, and 0.125 % (v/v) added to 48 h preformed biofilm of <i>P. aeruginosa</i> PseA	59
Figure 2.5	Cell-free extract of <i>Nocardiopsis</i> sp. EMB25 and <i>Nocardia</i> sp. EMB30, isolated in the lab, were used at concentrations 0.75 %, 0.5 %, 0.25 %, and 0.125 % (v/v) added to 48 h preformed biofilm of <i>P. aeruginosa</i> PseA	60
Figure 2.6	Phylogenetic tree based on 16S rRNA sequencing of selected strain EMB25 constructed using the neighbor-joining method performed in MEGA 7.0 software. The number of bootstrap replications was set to 1000. The strain used in this study is highlighted in box	61
Figure 2.7	The effect of cell-free extract of EMB25 was checked on preformed biofilm of various clinical strains, namely, <i>P. aeruginosa</i> , <i>K. pneumoniae</i> , and <i>E. coli</i> on 48 h preformed biofilm with replenishment of media at	62

	every 24 h	
Figure 2.8	The colony of <i>N. lucentensis</i> EMB25 (A) on ISP2 agar plate (B) Scanning electron micrographs at 1000 X magnification	64
Figure 2.9	Genomic comparison performed using BLAST Ring Image Generator (BRIG) tool revealing similarity with <i>N. dassonvillei</i> NOCA502F, and the circular map was created using CGview	66
Figure 2.10	Heat map depicting genomic comparison of <i>N. lucentensis</i> EMB25 based on orthoANI values	68
Figure 2.11	Gene ontology predicted using DIAMOND Blast P program	69
Figure 2.12	The Kyoto Encyclopaedia of Genes and Genomes (KEGG) function annotation of <i>N. lucentensis</i> EMB25	70
Figure 2.13	Distribution of <i>N. lucentensis</i> EMB25 genes into subsystem categories. The numbers in parentheses show the counts of genes with specific functions	75
Figure 2.14	(A) The antibacterial activity of <i>N. lucentensis</i> EMB25 using agar-plug assay (B) The effect of <i>N. lucentensis</i> EMB25 extract on preformed biofilm of <i>P. aeruginosa</i> PseA and cell count (C) Confocal microscopic images of <i>P. aeruginosa</i> PseA (i) control, (ii) post-treatment with the extract	78
Figure 2.15	Disc diffusion assay showing antibacterial activity against <i>S. aureus</i> and MRSA	79
Figure 3.1	The effect of ethyl acetate extract (25-0.097 $\mu\text{g}/\mu\text{L}$) on preformed 48 h biofilm of <i>P. aeruginosa</i> PseA (shown in black bars) and cell viability percentage as estimated using XTT assay (shown in red symbols) ($p < 0.05$)	91

Figure 3.2	The effect of ethyl acetate extract on eradication of 48 hours preformed biofilm of <i>P. aeruginosa</i> . The CLSM images of the biofilm of <i>P. aeruginosa</i> PseA untreated and after treatment for 24 hours onto glass coverslips at two different concentrations, 3.125 µg/µL and 25 µg/µL in TSB media at 30 °C were evaluated. The bacterial biomass was stained using the BacLight LIVE/DEAD viability kit after removing the planktonic cells. Live cells were labelled using the Syto 9 dye, while propidium iodide was used to stain dead cells (Scale bar, 10 µm)	93
Figure 3.3	The effect of ethyl acetate extract on eradication of 48 hours preformed biofilm of <i>P. aeruginosa</i> PseA. The quantification of <i>P. aeruginosa</i> PseA biofilms after treatment was performed by 3D imaging in Imaris 8.1 software. Data are mean from 3 independent experiments ± SD	94
Figure 3.4	Dose-dependent inhibition of <i>Nocardiopsis lucentensis</i> strain EMB25 ethyl acetate extract on the formation of <i>P. aeruginosa</i> PseA biofilm (ns, non-significant, **p<0.01; ****p<0.0001)	95
Figure 3.5	Growth curve of <i>P. aeruginosa</i> PseA in the presence of BIC ₅₀ (1.56 µg/µL), 12.5 µg/µL and highest concentration (25 µg/µL) used in the study	96
Figure 3.6	Estimation of virulence factor production at different organic extract concentrations (1.56 µg/µL and 25 µg/µL) (A) Pyocyanin (B) Rhamnolipid and (C) swarming motility assay. Data are mean from 3 independent experiments ± SD. Asterisks indicate the significant differences in comparison to untreated samples (**p<0.01; ***p<0.001; ****p<0.0001)	98
Figure 3.7	The effect of ethyl acetate extract on biofilm inhibition of <i>P. aeruginosa</i>	99

analyzed using FESEM at 5000X, 2500X and 500X magnification. The images were taken after treatment for 24 h onto glass coverslips at two different concentrations 1.56 µg/µL and 25 µg/µL in TSB media at 30°C

Figure 3.8	Comparison of binding of 3-oxo-C(12)-acylhomoserine lactone (PDB:2UV0) with (A) C 30, (B) C 15, (C) C 12, (D) C 58, (E) C 5, (F) C 61 to LasR. Metabolites bound to the active site pocket of LasR are superimposed on autoinducer shown in green stick. LasR is shown as ribbon with its N- and C-terminus labelled and the compounds are represented in sticks of different colours	104
Figure 3.9	Comparison of binding of N-butanoyl-L-homoserine lactone with (A) C 58, (B) C 15, (C) C 5, (D) C 30, (E) C 12, (F) C 10 to Alphafold model of RhlR. Metabolites bound to the active site pocket of LasR are superimposed on auto-inducer shown in green stick. RhlR is shown as ribbon with its N- and C-terminus labelled and the compounds are represented in sticks of different colors	105
Figure 3.10	Relative gene expression of various quorum sensing genes involved in biofilm formation. Data is plotted as mean of three biological replicates	109
Figure 4.1	The antimicrobial agar-plug method	114
Figure 4.2	Agar-plug assay showing antimicrobial activity of isolated <i>Streptomyces</i> sp. EMB24, <i>Streptomyces variabilis</i> EMB27, <i>Streptomyces</i> sp. EMB28, and <i>Streptomyces griseorubens</i> EMB29 against clinical strains: <i>E. coli</i> , <i>P. aeruginosa</i> , <i>S. aureus</i> and ATCC strains: <i>P. aeruginosa</i> ATCC 27853, <i>E. coli</i> ATCC 25922, <i>S. aureus</i> ATCC 25923	120
Figure 4.3	Agar-plug assay showing antimicrobial activity of isolated <i>Streptomyces</i> sp. EMB24, <i>Streptomyces variabilis</i> EMB27, and <i>Streptomyces</i>	121

griseorubens EMB29 against *N. gonorrhoeae* WHO (F), azithromycin-resistant *N. gonorrhoeae*, tetracycline-resistant *N. gonorrhoeae*, MRSA, *K. pneumoniae*, and *Acinetobacter baumannii*

Figure 4.4	Comparative analysis of 16S rRNA sequences from 20 isolates of <i>Streptomyces</i> sp. strain EMB24 with closely matched sequences using the BLASTn program at NCBI. The phylogenetic tree was constructed using the neighbor-joining method implemented in MEGA 7.0 software, with 1000 bootstrap replications	124
Figure 4.5	Comparative genome analysis using BLAST Ring Image Generator (BRIG software. <i>Streptomyces</i> sp. EMB24 strain genome assembly showed top hit to <i>Streptomyces</i> sp. ETH9427	125
Figure 4.6	Gene Ontology (GO) annotations for predicted protein-coding genes	126
Figure 4.7	The Kyoto Encyclopaedia of Genes and Genomes (KEGG) function annotation of <i>Streptomyces</i> sp. EMB24	127
Figure 4.8	Functional classification of proteins in <i>Streptomyces</i> sp. EMB24 using Clusters of Orthologous Groups of proteins (KOG). The pie graph illustrates the distribution of protein functions. Each segment represents a distinct functional category, with the numbers in parentheses denoting the gene counts associated with specific functions	132
Figure 4.9	Proposed BGCs of bioactive compounds in <i>Streptomyces</i> sp. strain EMB24 (A) depicts the putative BGC responsible for the production of Naphthyridinomycin (B) illustrates the proposed BGC associated with the synthesis of Curamycin (C) presents the hypothetical BGC believed to be involved in the production of Alkylresorcinol in <i>Streptomyces</i> sp. strain EMB24	134

Figure 5.1	UV-vis spectra of synthesized AgNPs: (A) effect of AgNO ₃ concentration varying from 0.25 mM to 3 mM (B) effect of incubation time ranges from 4 h to 24 h	146
Figure 5.2	Characterization of synthesized AgNPs by dynamic light scattering (DLS) (Malvern Zetasizer Na)	147
Figure 5.3	Characterization of synthesized AgNPs by XRD pattern (Rigaku Ultima IV advance benchtop X-ray diffractometer)	148
Figure 5.4	FTIR spectrum of synthesized AgNPs (Niclot, 6700)	149
Figure 5.5	FESEM of synthesized AgNPs (FEI Company, Netherland, Model: FEI Quanta 200 F SEM)	150
Figure: 5.6	EDX spectrum of synthesized AgNPs	151
Figure 5.7	Antibacterial activity of synthesized AgNPs (Syn_AgNPs) and commercial AgNPs (Com_AgNPs) against <i>E. coli</i> , <i>P. aeruginosa</i> , and <i>S. aureus</i>	152
Figure 5.8	Antibacterial activity of synthesized AgNPs (Syn_AgNPs) and commercial AgNPs (Com_AgNPs) against tetracycline-resistant <i>N. gonorrhoeae</i> , <i>N. gonorrhoeae</i> WHO F and MRSA	154
Figure 5.9	Time-dependent killing kinetic assays of AgNPs against MRSA. The concentrations used in the assay are equivalent to and higher than the MICs observed	155
Figure 5.10	Time-dependent killing kinetic assays of AgNPs against <i>P. aeruginosa</i> PseA. The concentrations used in the assay are equivalent and higher than the MICs observed	156
Figure 5.11	The release of nucleic acids and proteins were evaluated spectrophotometrically (A) <i>P. aeruginosa</i> PseA at AgNPs concentrations	157

	85 and 170 µg/mL and (B) MRSA at AgNPs concentration 42 and 84 µg/mL	
Figure 5.12	Propidium iodide dye uptake assay performed periodically in the presence of AgNPs (A) <i>P. aeruginosa</i> PseA at AgNPs concentrations 85 and 170 µg/mL and (B) MRSA at AgNPs concentrations 42 and 84 µg/mL	158
Figure 5.13	The Field Emission Scanning Electron Microscopy (FESEM) (FEI Company, Netherland, Model: FEI Quanta 200 F SEM) images of <i>P. aeruginosa</i> PseA after a 12-hour exposure to AgNPs at 100 µg/mL, captured at magnifications of 25,000X (A and B: control, C and D: test)	159
Figure 5.14	The Field Emission Scanning Electron Microscopy (FESEM) (FEI Company, Netherland, Model: FEI Quanta 200 F SEM) images of MRSA after a 12-hour exposure to AgNPs at 50 µg/mL, captured at magnifications of 25,000X (A: control, D: test), 10,000X (B: control, E: test), and 5,000X (C: control, F: test))	160
Figure 5.15	Transmission electron microscopy (TEM) images of <i>P. aeruginosa</i> PseA and MRSA after exposure to AgNPs at 100 µg/mL and 50 µg/mL, respectively, using TECNAI G20 HR-TEM 200Kv, Thermo Scientific	161
Figure 5.16	The effect of AgNPs on biofilm inhibition of <i>P. aeruginosa</i> at 50, 25, 12.5, and 6.25 µg/mL concentrations	162
Figure 5.17	The confocal microscopy images in the presence and absence of AgNPs depicting biofilm inhibition at 50 µg/mL concentration (Laser Scanning Confocal Microscope: LSM 880, Carl Zeiss)	163
Figure 5.18	The effect of AgNPs on the preformed biofilm over 48 h of <i>P. aeruginosa</i> PseA at 50, 25, 12.5, and 6.25 µg/mL concentrations. FESEM images	164

confer no effect on preformed biofilm in the presence of AgNPs at 50
μg/mL concentration

List of Tables

Table 1.1	Recent biofilm inhibitors reported from Actinobacteria	39
Table 1.2	Bioactive compounds isolated from <i>Streptomyces</i> sp.	41
Table 1.3	Compounds isolated from marine actinobacteria with various biological activities in recent years	44
Table 2.1	16S rRNA sequencing of isolated actinobacteria	57
Table 2.2	Carbon source Utilization by <i>N. lucentensis</i> EMB25	63
Table 2.3	The assembly statistics of <i>N. lucentensis</i> EMB25	65
Table 2.4	The ortho ANI values of <i>N. lucentensis</i> EMB25 with closely related <i>Nocardiosis</i> sp.	67
Table 2.5	Overview of 24 secondary metabolic biosynthesis gene clusters of <i>N. lucentensis</i> EMB25 detected by antiSMASH 2.0 server	72
Table 2.6	BAGEL4 webtool listed the AOI (area of interest) present in <i>N. arvandica</i> DSM4527 and <i>N. lucentensis</i> EMB25	76
Table 3.1	Primers used in RT-PCR	90
Table 3.2	Metabolites obtained from GC-MS	100
Table 3.3	List of compounds with docking scores better than -6.0	103
Table 3.4	Residues within 4 Å of the docked compounds	106
Table 3.5	ADME properties of compounds showing docking score better than -6	108
Table 4.1	The zone of inhibition observed at different time intervals	122
Table 4.2	The genomic characteristics of <i>Streptomyces</i> sp. strain EMB24	123
Table 4.3	Overview of 17 secondary metabolic biosynthesis gene clusters	129

of *Streptomyces* sp. strain EMB24 detected by antiSMASH 2.0
server

Table 5.1 The Minimum inhibitory concentration values are summarized 153
for *E. coli*, *P. aeruginosa*, PseA and MRSA